Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: A case report

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 688-690

  Shiozawa, Kazue ^a   Watanabe, Manabu ^a   Takenaka, Hiroki ^a   Nagai, Hidenari ^a   Ishii, Koji ^a   Sakai, Ken ^a   Sumino, Yasukiyo ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Complication; Hepatocellular carcinoma; Sorafenib; Tumor lysis syndrome

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; CITRATE SODIUM; CREATININE; POTASSIUM; SORAFENIB; URIC ACID;

AGED; ARTERIAL GAS; ARTICLE; BLOOD CHEMISTRY; BLOOD GAS ANALYSIS; CANCER GROWTH; CANCER STAGING; CASE REPORT; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEPATITIS C; HUMAN; INTRAVENOUS ADMINISTRATION; KIDNEY DYSFUNCTION; LIVER CELL CARCINOMA; METABOLIC ACIDOSIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URINALYSIS;

ACIDOSIS, RESPIRATORY; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; HYPERURICEMIA; LIVER NEOPLASMS; PYRIDINES; TOMOGRAPHY, X-RAY COMPUTED; TUMOR LYSIS SYNDROME;

EID: 78149262098     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Cairo MS and Bishop M: Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004; 127:3-11.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
3. Lehner SG, Gould JE, Saad WE, Brown DB: Tumor lysis syndrome after radiofrequency ablation of hepatocellular carcinoma. AJR Am J Roentgenol 2005; 185:1307-1309.
4. Hsieh PM, Hung KC, Chen YS: Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: Case reports and literature review. World J Gastroenterol 2009; 15:4726-4728.
5. Huang WS and Yang CH: Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient. World J Gastroenterol 2009; 15:4464-4466.
6. Alkhuja S, Ulrich H: Acute renal failure from spontaneous acute tumor lysis syndrome: a case report and review. Ren Fail 2002; 24:227-232.
7. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004; 116:546-554.
8. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT: Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009; 115:428-436.
9. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM: TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
10. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G: Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007; 110:1376-1384.
11. Kintzel PE: Anticancer drug-induced kidney disorders. Drug Saf 2001; 24:19-38.
12. Kelly RJ, Billemont B, Rixe O: Renal toxicity of targeted therapies. Targ Oncol 2009; 4:121-133.